

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934

SEPTEMBER 30, 1999

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

(Address of principal executive offices)

336-229-1127

(Registrant's telephone number, including area code)

ITEM 5. OTHER EVENTS

On September 30, 1999, the Company and Hycor Biomedical Inc. announced the signing of a three-year supply agreement. Under the terms of the agreement, Hycor will serve as the primary supplier of IN VITRO allergy testing reagents to the Company.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
INFORMATION AND EXHIBITS

- (c) Exhibit
20 Press release of the Company dated
September 30, 1999.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Registrant)

By:/s/ BRADFORD T. SMITH

Bradford T. Smith
Executive Vice President,
General Counsel, Secretary
and Compliance Officer

Date: October 4, 1999

Hycor CONTACT: Reg Jones
Senior Vice President and
Chief Financial Officer
(714) 933-3000

LabCorp CONTACT: Pam Sherry
Vice President Investor Relations
(336) 584-5171, Ext. 4855

FOR IMMEDIATE RELEASE

HYCOR AND LABCORP-REGISTERED TRADEMARK- ANNOUNCE SUPPLY
AGREEMENT

GARDEN GROVE, CALIFORNIA AND BURLINGTON, NORTH CAROLINA -
SEPTEMBER 30, 1999 - Hycor Biomedical Inc. (NASDAQ: HYBD)
and Laboratory Corporation of America-Registered Trademark-
Holdings (LabCorp-Registered Trademark-) (NYSE: LH) today
announced the signing of a three-year supply agreement.
Under the terms of the agreement, Hycor will serve as the
primary supplier of IN VITRO allergy testing reagents to
LabCorp.

J. David Tholen, Hycor President and Chief Executive
Officer, said, "The signing of the agreement formalizes the
relationship between Hycor and LabCorp. Although we have
done business together for many years, this agreement
strengthens our relationship and provides Hycor
opportunities for additional growth. We are proud to be a
supply partner to one of the largest allergy testing
laboratories in the United States."

"Since allergic disease affects some 20% of the general
population, LabCorp continues to build capabilities to test
for a wide range of allergens and distinguish allergy
problems for the patients we serve," said Dr. Myla Lai-
Goldman, LabCorp Executive Vice President, Chief Scientific
Officer and Medical Director. "Hycor offers a broad
allergen menu, and augments LabCorp's strategy of expanding
its array of specialized assays with innovative technologies
to aid in the diagnosis and treatment of disease."

The matters discussed in this report are forward-looking
statements that involve risk and uncertainties that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements. These risks
and uncertainties include, but are not limited to, economic,
competitive, governmental and technological factors
affecting the Companies' operations, markets, products,
services and prices and other factors discussed in the
Companies' filings with the Securities and Exchange
Commission.

Hycor Biomedical Inc. discovers, develops, manufactures, and
markets diagnostic products for a variety of human medical
conditions. These products include high quality automated
instrument and reagent systems that use blood samples to
test for more than 900 different allergies and autoimmune
disorders, and urinalysis controls and disposable products
under the KOVA-Registered Trademark- brand, the market
leader in standardized microscopic urinalysis. Hycor
products are used by physicians and clinical laboratories
all over the world to provide accurate, reliable test
results for physicians and their patients. Headquartered in
Garden Grove, California with facilities in Germany,
Scotland, and France, Hycor employs more than 175 people
worldwide and serves customers in more than 50 countries.
Visit Hycor's web site at <http://www.hycorbiomedical.com>.

Laboratory Corporation of America-Registered Trademark-
Holdings (LabCorp-Registered Trademark-) is a national
clinical laboratory with annual revenues of \$1.6 billion in
1998. With approximately 18,400 employees and over 100,000
clients nationwide, the company offers more than 2,000

clinical tests, ranging from simple blood analyses to more sophisticated technologies. Included in LabCorp's network of 25 major laboratories are three Centers of Excellence. The Center for Molecular Biology and Pathology, in Research Triangle Park (RTP), North Carolina, develops applications for polymerase chain reaction (PCR) technology. Its Center for Occupational Testing in RTP is the world's largest substance abuse testing facility, and the Center for Esoteric Testing in Burlington, North Carolina, performs the largest volume of rare analyses in the network. LabCorp's clients include physicians, state and federal governments, managed care organizations, hospitals, clinics, pharmaceutical and Fortune 1000 companies, and other clinical laboratories. Visit LabCorp's web site at <http://www.labcorp.com>.

###